USFDA approves Mylan, Biocon's Fulphila, the first biosimilar to Neulasta Ruby Khatun Khatun6 Jun 2018 5:00 AM GMTHERTFORDSHIRE/PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's...
EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars Ruby Khatun Khatun2 Dec 2017 4:30 AM GMTHERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
Biocon launches colon cancer drug in India, priced Rs 24,000 Ruby Khatun Khatun24 Nov 2017 4:31 AM GMTBengaluru: Biocon Ltd has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types...